Embecta

Parsippany, United States Founded: 2022 • Age: 4 yrs Listed
Insulin delivery solutions including pen needles and syringes are manufactured.

About Embecta

Embecta is a publicly listed company based in Parsippany (United States) founded in 2022. Insulin delivery solutions including pen needles and syringes are manufactured. The company has 2,100 employees. Embecta has completed 1 acquisition, including Owen Mumford. Its chief executive, as recorded, is Devdatt Kurdikar. Its website embecta.com draws about 60 thousand monthly visits. Its Indian entity Embecta India Private Limited reported revenue of ₹24.06 Cr. Embecta offers products and services including Pen Needles and Insulin Syringes. Its focus areas include Life Sciences, Diabetes, Medical Devices and Therapeutic Devices.

Company details

Embecta was founded in 2022 and is headquartered in Parsippany, United States. Operations are centered in the healthcare sector, with a focus on diabetes management. Insulin delivery products such as pen needles and syringes are developed and supplied to support daily care needs. Efforts are directed toward enhancing injection experiences through innovation. Educational resources and guidance on proper injection techniques are also made available to users.

  • Headquarters Parsippany, United States
  • Employees 2,100
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website embecta.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Embecta Corp.
Operational Areas
Key Metrics
  • Indian entity revenue
    ₹24.06 Cr

    FY 2025 · +6% YoY

  • Indian entity net profit
    ₹49.8 Lakh

    FY 2025 · 2% margin

  • Indian entity EBITDA
    ₹3.11 Cr

    FY 2025 · 13% margin

  • Employee Count
    2,100
  • Investments & Acquisitions

Products & Services of Embecta

Embecta offers a comprehensive portfolio of products and services, including Pen Needles and Insulin Syringes.

Pen Needles
Medical Devices

Pen needles are manufactured for use in insulin delivery to aid diabetes management.

Insulin Syringes
Medical Devices

Insulin syringes are supplied for administering insulin as part of diabetes care practices.

Apps and channels of Embecta

its YouTube channel embecta has 676 subscribers and 30 videos.

embecta
YouTube 676 subscribers 30 videos Autos & Vehicles
Open channel

Videos from Embecta

The most watched videos on Embecta's YouTube channel, embecta (676 subscribers). Click a video to play it here.

Improving Diabetes Self-Care, One New Needle at A Time
389.4K views
Celebrating 100 Years of Commitment to the Diabetes Community
104.9K views
A life unlimited. Andrea’s Diabetes Journey
67.2K views
A life unlimited. Fannie’s Diabetes Journey
63.8K views

More on embecta.

Board of directors of Embecta India Private Limited (Embecta)

Embecta India Private Limited is the primary company behind Embecta. The board of Embecta India Private Limited currently have 3 directors; the longest-serving is Sushil Shadija, appointed in 2022. 4 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sushil Shadija
DIN 09523985
Whole-time director15 Mar 20224 yrs 8 moEmbecta India Private Limited
Jeffrey Zimmerman Mann
DIN 09526647
Director15 Mar 20224 yrs 8 moEmbecta India Private Limited
Michael John Piotrowski
DIN 10848120
Director06 Dec 20241 yr 11 moEmbecta India Private Limited

People of Embecta

79 people are tracked at Embecta (49 in leadership, 30 in team); the tracked headcount is 2,100.

NameRoleGroup
Devdatt Kurdikar
CEOLeadership
Jean Casner
Sr. Vice President & CHROLeadership
Arpan Gandhi
Senior Director - National Sales And GPOLeadership
Avital Merl-Margulies
Senior Director, Regulatory ComplianceLeadership
Rachael Roberts
Vice President Of SalesLeadership
Christine Seethaler
Head Of Legal OperationsLeadership
Ketan D. Patel
Vice President Of TaxLeadership
Geoff Sisler
Vp, Total Rewards & HR OperationsLeadership
Donald Broedlin
Vice President, Strategic AccountsLeadership
Antonio Mulé
Vice President, Global Commercial FinanceLeadership
Jake Elguicze
Svp, Chief Financial OfficerLeadership
Roberto Bettin
Amministratore Delegato - General Manager, Southern EuropeLeadership
Nirav Panchal
Associate DirectorLeadership
Claudia Karpat
Legal Director EMEA Region & Corporate InternationalLeadership
Katie Ellis
Key Account Director- Retail & DistributionLeadership
Ray Jacobus
Senior Director Strategic Pricing & Contracting - North AmericaLeadership
Ashley Caldwell
Senior Director, Retail And DistributionLeadership
Shoua X.
Sr. Director, North America Commercial And Global Head Of Ethics, Compliance And PrivacyLeadership
Elyse Robertson
Sr. Director HRLeadership
Adam Hansinger
National Account DirectorLeadership

59 more people are available in the full profile.

Premium access

Complete people profiles for Embecta

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Embecta

Embecta is a publicly listed company on the NASDAQ with ticker symbol EMBC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date22 Mar 2022
  • Listed onNASDAQ: EMBC
  • Listed entityEmbecta Corp.
  • Exchange sectorHealth technology
  • ISINUS29082K1051
  • Share price$6.20 (+3.51% on the day) · 2026-10-13
  • Market capitalisation$351.3M
  • Price to earnings4.2
  • EPS (diluted, trailing year)$1.48
  • Dividend yield5.16%
  • Volume (last session)732,864

Financials of Embecta

Figures of Embecta India Private Limited, the primary company behind Embecta, for FY 2025. Revenue was ₹24.06 Cr (+6% year on year). Net profit was ₹49.8 Lakh (2% margin). EBITDA was ₹3.11 Cr (13% margin). Revenue has grown at a compounded annual rate of +204% over three years.

  • ₹24.06 CrRevenue · FY 2025 · +6% YoY
  • ₹49.8 LakhNet profit · 2% margin
  • ₹3.11 CrEBITDA · 13% margin
  • ₹6 LakhPaid-up capital
  • 39Employees (provident fund records)
  • +204%Revenue CAGR, 3 years
Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$1.08B$95.4M$380.4M
2024$1.12B$78.3M$216.7M
2023$1.12B$70.4M$262.3M
2022$1.13B$223.6M$409.8M
2021$1.17B$415.0M$530.0M

Balance sheet, profit and loss, cash flow and ratios of Embecta India Private Limited are on its company page.

Premium access

Detailed financial statements for Embecta

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Embecta

Embecta has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Owen Mumford.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Disposables for drug delivery and capillary blood sampling are manufactured.
owenmumford.comOxford, United Kingdom1952Mar 2026$200.08M
Premium access

Complete acquisition details for Embecta

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Embecta

3 dated milestones of Embecta across 4 years, from founding to its latest funding, stage changes and deals.

  1. Founded Embecta is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Owen Mumford.

Web traffic of Embecta

The website of Embecta (embecta.com) receives about 60.1K visits a month.

  • Monthly visits
    60.1K

    ▼ 13.9% vs previous month

Similar websites

Websites whose visitors overlap most with Embecta. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
medicinalsupplies.com
medicinalsupplies.com
100%
#2,604,369–

Top companies in Diabetes

3 companies that operate in the same segment as Embecta (Diabetes) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of devices for continuous glucose monitoring and manual insulin delivery
2008San Diego, California, United StatesUSD 100.73 MUSD 1.02 B2,650
Wearable glucose monitoring patches are provided for real-time data tracking.
1999San Diego, California, United StatesUSD 52.5 MUSD 4.66 B10,300
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Embecta

Premium access

Complete news archive for Embecta

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Embecta

Embecta was founded in 2022.

Embecta is headquartered in Parsippany, United States. It is registered at Parsippany, New Jersey, United States.

Devdatt Kurdikar is the CEO of Embecta, as recorded in our data.

Embecta has 2,100 employees.

The primary company behind Embecta, Embecta India Private Limited, reported revenue of ₹24.06 Cr for FY 2025, up 6% year on year.

Embecta was founded in 2022 and is headquartered in Parsippany, United States. Operations are centered in the healthcare sector, with a focus on diabetes management. Insulin delivery products such as pen needles and syringes are developed and supplied to support daily care needs. Efforts are directed toward enhancing injection experiences through innovation. Educational resources and guidance on proper injection techniques are also made available to users.

Embecta offers Pen Needles and Insulin Syringes.

Yes, Embecta is publicly traded on NASDAQ under the ticker symbol EMBC.

Embecta has made 1 acquisition, including Owen Mumford.

Embecta operates through Embecta India Private Limited.

The legal entities of Embecta currently have 3 directors, including Sushil Shadija, Jeffrey Zimmerman Mann, Michael John Piotrowski.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available